However, the quantity of DNA used per unit bodymass and the route chosen might make these vaccines unsuitable for human use. (Guy et al, Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine, Vaccine 19:1794, 2001). [0006] Currently, one of the options available to infants, who are at a high risk for developing RSV infection, is passive immuniza